Azathioprine + infliximab showed no clear difference in adverse events compared with infliximab (moderate certainty).
Azathioprine + infliximab showed no clear difference in withdrawals due to adverse events compared with infliximab (moderate certainty).
Azathioprine + infliximab probably leads to lower serious adverse events compared with infliximab (moderate certainty).
It is very uncertain whether azathioprine and infliximab changes maintenance of remission compared with infliximab (very low certainty).
It is very uncertain whether azathioprine and infliximab changes adverse events compared with infliximab (very low certainty).
It is very uncertain whether azathioprine and infliximab changes withdrawals due to adverse events compared with infliximab (very low certainty).
It is very uncertain whether azathioprine and infliximab changes serious adverse events compared with infliximab (very low certainty).
Azathioprine or 6‐mercaptopurine probably leads to lower clinical relapse compared with placebo (moderate certainty).
It is very uncertain whether azathioprine or 6‐mercaptopurine changes radiologic relapse compared with 5‐aminosalicylic acid (very low certainty).
It is very uncertain whether azathioprine or 6‐mercaptopurine changes surgical relapse compared with 5‐aminosalicylic acid (very low certainty).
Azathioprine or 6‐mercaptopurine showed no clear difference in adverse events compared with 5‐aminosalicylic acid (low certainty).
It is very uncertain whether azathioprine or 6‐mercaptopurine changes serious adverse events compared with 5‐aminosalicylic acid (very low certainty).
Azathioprine or 6‐mercaptopurine may leads to higher withdrawal due to adverse events compared with 5‐aminosalicylic acid (low certainty).
It is very uncertain whether azathioprine or 6‐mercaptopurine changes clinical relapse compared with anti TNF‐α (very low certainty).
It is very uncertain whether azathioprine or 6‐mercaptopurine changes endoscopic relapse compared with anti TNF‐α (very low certainty).
The review found no eligible studies for this question.
Azathioprine or 6‐mercaptopurine showed no clear difference in adverse events compared with anti TNF‐α (low certainty).
Azathioprine or 6‐mercaptopurine showed no clear difference in endoscopic relapse compared with placebo (low certainty).
It is very uncertain whether azathioprine or 6‐mercaptopurine changes serious adverse events compared with anti TNF‐α (very low certainty).